66 results about "Plasma levels" patented technology

The invention discloses a child allergic asthma marker and application thereof, and belongs to the technical field of biological medicine. Through detection of clinical samples, compared with healthy control children, the blood plasma BCAA level of children with allergic asthma is remarkably increased, and the kit has good diagnostic value. After medication treatment, the blood plasma BCAA level of children with allergic asthma is obviously reduced, and the composition has a good treatment and prognosis value. Therefore, the plasma BCAA can be used as a marker for diagnosis and prognosis of the children allergic asthma, and a foundation is laid for guiding clinical medication.

Disclosed is a method of reducing plasma level of macrophage migratory inhibitory factor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to enhance dextromethorphan plasma levels.

A computer implemented method for determining a dosage of rivaroxaban for administering to a patient, the method comprising: receiving patient data relating to a patient, wherein the patient data includes a kidney function metric; processing the patient data with a dosage calculator to determine the dosage of rivaroxaban for administering to the patient, wherein the dosage calculator is derived from a plasma level prediction model; and indicating the dosage.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.

This invention relates to methods of lowering plasma levels of endothelial lipase (EL) in patients in need thereof comprising administering MEDI5884 to subjects at a dose of from about 50 mg to about 600 mg per month.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.

Blood plasma samples are obtained from type 2 diabetes (T2D) patients and a concentration of F2-isoprostanes (F2I) in the sample is quantified. Plasma F2I levels assess oxidative stress levels in the patient and indicate elevated risk of T2D-associated complications including incident clinical fracture, cardiovascular complications, renal disease, etc. in the T2D cohort, independently of other risk factors. Fracture risk in the T2D population is heightened for a given bone mineral density (BMD) and is underestimated by evaluation tools such as Fracture Risk Assessment Tool (FRAX). The patient's BMD T-score can be adjusted based on F2I concentrations, capturing reductions in bone quality as well as quantity that lead to the elevated fracture risk in T2D patients. These diagnostic procedures can be effectively deployed in a patient's course of treatment merely by supplementing an existing blood panel, rather than with a separate blood draw.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for excreting dampness and strengthening heart as well as a preparation method and application thereof. The active ingredient of the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 3-10 parts of prepared radix aconiti carmichaeli, 5-15 parts of rhizoma zingiberis, 5-15 parts of honey-fried licorice root, 10-30 parts of radix pseudostellariae, 5-15 parts of wine-processed radix cyathulae, 10-30 parts of radix salviae miltiorrhizae, 3-10 parts of pericarpium citri reticulatae, 10-30 parts of rhizoma alismatis and 5-15 parts of radix platycodonis. The traditional Chinese medicine has the effects of tonifying deficiency, dispelling excess, tonifying qi, nourishing yin, excreting dampness and promoting blood circulation, treating root causes by tonifying qi and nourishing yin and treating symptoms by excreting dampness and promoting blood circulation, and achieving the effect of treating both symptoms and root causes. Clinical research shows that the traditional Chinese medicine composition not only can reduce the plasma NT-proBNP level of a patient with ejection fraction retention type heart failure, but also can improve the score of the patient in the Life Quality Scale of Clinical Myocardiopathy Patient, and can be used for treating related diseases such as ejection fraction retention type heart failure and the like.

The present disclosure provides methods and materials related to MANPs. In one embodiment, the present disclosure provides a method for treating hypertension with metabolic syndrome by administering MANPs to a patient in need of such treatment. In one embodiment, the present disclosure provides a method comprising administering MANPs to a patient to lower blood pressure (BP). In one embodiment, the method of the present disclosure is employed to treat patients with low baseline cGMP levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to increase or improve plasma cGMP levels, plasma ANP-like peptide levels, insulin sensitivity, or plasma NEFA levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to lower plasma glucose levels.

A method for administering a dosage of Apixaban to a patient for the treatment or prevention of thrombosis, the method comprising: administering a dosage of Apixaban to the patient, wherein the dosage of apixaban is determined by: receiving patient data relating to a patient, wherein the patient data includes a kidney function metric of the patient; and processing, using one or more processors, the patient data with a dosage calculator to determine the dosage of Apixaban for the patient, wherein the dosage calculator is derived from a plasma level prediction model that predicts Apixaban drug plasma levels, and the dosage calculator determines the dosage for the patient based in part on the kidney function metric of the patient.

This disclosure provides compounds of formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels. [Formula 1] TIFF2026525345000055.tif58128

A preparation method for a novel compound which reduces blood plasma Lp(a) levels, and an intermediate compound of the novel compound. The novel compound is biochemically effective and physiologically active.

The invention discloses application of a gene editing virus interfering expression and secretion of enzyme prototype cathepsin D in brain trauma, belongs to the field of gene functions and application, and finds that brain injury is aggravated and nerve dysfunction is aggravated due to the fact that the level of the enzyme prototype cathepsin D in plasma is increased due to the brain trauma through detection. The mechanism is as follows: the enzyme prototype cathepsin D enhances the transendocytosis effect of cerebral vascular endothelial cells after brain trauma, so that plasma inflammatory factors are gathered in damaged brain tissues; meanwhile, the expression of cerebrovascular endothelial cells VCAM-1 is also up-regulated, and neutrophil infiltration in an injured brain region after brain trauma is intensified. Research finds that down-regulation of plasma enzyme prototype cathepsin D can alleviate inflammatory factor concentration and neutrophil density in a brain injury area after trauma, and alleviate neurological function impairment of mice. Aiming at the functions of the plasma prototype cathepsin D, a strategy for reducing the plasma level of the plasma prototype cathepsin D by a gene editing technology for interfering the prototype cathepsin D is provided for treating the cerebral trauma.

To provide a method for treatment of patients suffering from a hyperinflammatory syndrome without hampering the inflammatory response of the patients or at least to a much lesser extent.SOLUTION: Provided is an antagonist of a mammalian P2X7 receptor (P2X7R) for use in the treatment of a hyperinflammatory syndrome in a mammalian patient, by primary lymph node targeted administration of the P2X7R antagonist in the patient to a concentration of the antagonist of the mammalian P2X7R in the targeted lymph nodes that is above the maximal tolerable plasma level of the antagonist in the mammal.SELECTED DRAWING: None

The present disclosure generally provides compositions and methods for increasing the activity of an annexin protein to treat a cellular membrane injury in a patient in need thereof. In some aspects, the disclosure provides methods of treating a patient suffering from a nerve injury comprising administering a therapeutically effective amount of a composition comprising an agent that increases the activity of an annexin protein. In further aspects, the disclosure provides methods of reducing serum or plasma level of lactate dehydrogenase (LDH), cardiac troponin T, cardiac troponin I, creatine kinase (CK), or a combination thereof, in a patient in need thereof, comprising administering a therapeutically effective amount of an agent that increases the activity of an annexin protein to the patient.

The invention relates to the technical field of medicine, in particular to a composition containing an angiotensin II receptor blocker and application of the composition in heart disease dilation medicine. The composition comprises an angiotensin converting enzyme inhibitor and an angiotensin II receptor blocker, and a small dose of ACEI and a large dose of ARB are combined to be used for dilating the heart disease. The traditional Chinese medicine composition has excellent effects in the aspects of reducing the left ventricular end diastolic anterior-posterior diameter or left-right diameter, plasma brain natriuretic peptide precursor (NT-pro BNP) plasma level, pulmonary arterial pressure and left ventricular ejection fraction, does not influence the normal levels of physiological indexes such as blood potassium, serum creatinine, urea nitrogen, alanine aminotransferase (ALT) and asparaginic acid aminotransferase (AST), and can be used for preparing a medicine for treating the left ventricular end diastole. The medicine can be applied to heart disease dilation medicines.

The invention discloses application of turmeric volatile oil in preparation of a medicine for preventing and treating acute lung injury. The turmeric volatile oil is extracted and prepared by adopting a steam distillation method, the turmeric volatile oil is subjected to characterization analysis in combination with UPLC (Ultra Performance Liquid Chromatography), and the influence of the turmeric volatile oil on rat lung indexes, lung tissue pathological changes and plasma IL-1beta, TNF-alpha and IL-6 levels is analyzed through LPS (Lipopolysaccharide)-induced replication of a rat acute lung injury model. The turmeric volatile oil is proved to have a remarkable technical effect in treating the acute lung injury. The invention provides new application of turmeric volatile oil in acute lung injury treatment, and provides a new natural medicine source for acute lung injury prevention and treatment.

Microvascular leak plays a critical role in the outcome of sepsis. Counteracting vascular leakage has recently raised a huge interest in the field but therapeutic targets and translation studies are crucially lacking. The inventors hypothesized that ANGPTL4 might counteract lipopolysaccharide-induced vascular hyperpermeability. Mechanistically, the inventors show that the C-terminal fragment of ANGPTL4 recapitulates full-length ANGPTL4 inhibition of vascular permeability by stabilizing endothelial cell adherent junctions whereas the N-terminus has no such effect. The inventors further demonstrate that giving human recombinant c- ANGPTL4 to mice prevents microvascular leak and mortality induced by LPS. In humans, the inventors describe the association between ANGPTL4 plasma level at time of inclusion and 90- day mortality in sepsis or septic shock patients French and European Outcome Registry in Intensive Care Units (FROG-ICU). In conclusion, the inventors demonstrate that suppressing vascular permeability by c-ANGPTL4 could be a novel therapeutic for the treatment of sepsis capillary leak syndrome. Either alone or in combination with existing drugs, c-ANGPTL4 could contribute to the reduction of mortality in patients with shock states.

The invention relates to the treatment of neurodegenerative diseases such as Parkinson patients with motor complications in need of Continuous Dopaminergic Stimulation. According to the invention a kit of pharmaceutical preparations is provided comprising levodopa and an AADC-inhibitor. Levodopa is applied via continuous subcutaneous infusion or by an oral modified release formulation and Continuous Dopaminergic Stimulation is achieved by almost complete inhibition of the peripheral levodopa metabolism. To reach far-going blockage of levodopa metabolism, an AADC-inhibitor (e.g., benserazide, carbidopa) is given orally in a much higher than normal dose and, as an indispensable prerequisite, the AADC-inhibitor has to be applied evenly distributed over the day. e.g., via a Modified Release formulation. In order to prevent levodopa conjugation over the COMT pathway, an oral COMT-inhibitor (e.g., opicapone) is also added. In addition, a drug-drug-interaction between the AADC-inhibitor and opicapone further increasing the activity of the former is likely to occur. The resulting effective inhibition of peripheral levodopa metabolism allows a marked reduction of the necessary (equivalent) levodopa (or prodrug) doses to 300-600 mg / day, which is, however, sufficient to reach high levodopa plasma levels of 1500 to 3000 ng / ml. The low daily levodopa dose is infused subcutaneously via minipump and is well-tolerated at the infusion site. Alternatively, the low daily levodopa dose is provided as an oral modified release formulation. The high steady-state levodopa plasma levels reached, allow effective Continuous Dopaminergic Stimulation-therapy for Parkinson's disease patients of any degree of severity. As additional benefit, the largely complete AADC-inhibition prevents the peripheral generation of dopamine and the cumbersome dopaminergic adverse effects (e.g., nausea, cardiovascular and gastro-intestinal adverse effects) are prevented.

A method of reducing elevated plasma levels of cholesterol in a subject is disclosed. Also disclosed is a method of treating hypercholesterolemia in a subject. The method comprises administering to the subject an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, in the absence of a cholesterol-lowering drug.

Dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion are described herein. The (S)-bupropion or the (R)-bupropion may be rich in deuterium, or may have a natural isotope abundance. These dosage forms may be administered upon eating or fasting to treat conditions described herein, to achieve certain pharmacokinetic parameters of bupropion or bupropion metabolites, and / or to increase dextromethorphan plasma levels.

The present disclosure provides methods for treating, preventing, ameliorates, inhibits, or delaying the onset of Leigh syndrome as well as methods for ameliorating, inhibiting, ameliorates, inhibits, or delaying the onset of its associated signs and / or symptoms, such as exercise-induced acid acidosis, and increases in plasma levels of growth factor 15 (GDF-15) and / or fibroblast growth factor (FGF-21) in a subject in need thereof comprising administering to the subject various compounds, mixtures of compounds or compositions, formulations or medicaments derived therefrom.

The present invention relates to a CXCR4 inhibitor compound for use in the treatment of a severe acute respiratory distress syndrome (sARDS), wherein the sARDS is characterized by a dysregulation of NETosis which may be measured by the plasmatic levels of cDNA, citrullinated histone H3, neutrophil elastase, interleukin-8, myeloperoxidase-DNA complexes and / or calprotectin. The present invention also relates to a method of prognostic of severe ARDS, a pharmaceutical composition for use in the treatment of severe acute respiratory distress syndrome (ARDS), a kit of prognostic of severe ARDS in a subject and the use of NETosis biomarkers.

The present disclosure provides compounds of the formula: and pharmaceutically acceptable salts thereof, and compounds of the formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.

The present disclosure provides orally administered pharmaceutical compositions that are effective in providing sustained plasma levels of a therapeutic peptide in a subject. The disclosed compositions are oral dosage forms comprising a large and / or poorly permeable cyclic peptide, a fatty acid salt, a cellulose-derived polymer, and one or more pharmaceutically acceptable excipients. Methods of preparing these compositions for oral administration, and methods of treatment comprising administering these compositions, are further provided. The disclosed methods and compositions provide for a sustained release of cyclic peptide drugs while also providing enhanced bioavailability relative to immediate-release formulations.

The present disclosure provides a method of treating or inducing cognitive preservation in a patient with Alzheimer's disease, comprising administering an effective amount of CT1812. The effective amount of CT1812 is 100 mg or 300 mg administered orally once daily. The method demonstrates improvements in cognitive outcomes compared to placebo across multiple measures including ADAS-Cog11, MMSE, ADCS-ADL, and ADCS-CGIC. The method demonstrates improvements in cognitive outcomes in patients with low plasma levels of phosphorylated tau 217 prior to administration.

This invention relates to methods and compositions useful in subjects with age- related macular degeneration, in particular dry age-related macular degeneration. It has been demonstrated that the CETP inhibitor obicetrapib increases the plasma level of pre-beta-1 HDL, as well as total plasma lutein, zeaxanthin and tocopherol. More in particular, it has been found that the levels of these lipophilic anti-oxidants are also particularly elevated in pre-beta-1 HDL, which can pass the BrM and reach the retina with relative ease. These constitute particularly strong support for the treatment of AMD using a CETP inhibitor. Thus, broadly stated, the present invention concerns the use of CETP inhibitors in the treatment of age related macular degeneration.